TMS Co

TMS Co Financial Leverage

The Financial Leverage (Equity Multiplier) of TMS Co (4891.T) as of Nov 4, 2026 is 1.03. In the previous year, Financial Leverage (Equity Multiplier) was 1.08 — a change of -3.96% (lower).

Financial Leverage

1.03

YoY

-3.96%

Last updated:

Financial Leverage (Equity Multiplier) of TMS Co is 2026 1.03 . Financial Leverage (Equity Multiplier) of TMS Co was 2025 1.08 . It decreases by -3.96% lower compared to the previous year.

The TMS Co Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2021
1.08 JPY
Jan 1, 2022
1.12 JPY
Jan 1, 2023
1.02 JPY
Jan 1, 2024
1.03 JPY
Jan 1, 2025
1.08 JPY
Jan 1, 2026
1.03 JPY
The TMS Co Financial Leverage history
YEARFinancial LeverageYoY
1.03-3.96%
1.08+4.74%
1.03+0.76%
1.02-8.63%
1.12+3.74%
1.08—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TMS Co Stock analysis

What does TMS Co do? TMS Co., Ltd. generates revenue through the research and development of pharmaceutical products and medical devices, focusing on drug candidates targeting soluble epoxide hydrolase (sEH). The company develops sEH inhibitors for inflammatory diseases, with its lead candidate TMS-007 undergoing clinical development for acute cerebral infarction. TMS-007 combines anti-inflammatory and thrombolytic effects by inhibiting sEH and acting on plasminogen. The follow-on product TMS-008 is in pre-clinical studies for various inflammatory diseases. The company collaborates with academia and research institutions for R&D results, leveraging external research to advance its pipeline. TMS Co., Ltd. targets the pharmaceutical market for inflammatory disease treatments, focusing on drug candidates with dual mechanisms of action. Its primary customers are pharmaceutical companies and research institutions seeking innovative therapeutic solutions. The company's pipeline includes TMS-007 for acute cerebral infarction and TMS-008 for broader inflammatory conditions, positioning itself in the biopharmaceutical segment. The firm's revenue model relies on advancing its pipeline through clinical and pre-clinical stages, with potential partnerships for further development and commercialization. TMS Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TMS Co stock

Financial Leverage (Equity Multiplier) of TMS Co is 1.03 in 2026.

Financial Leverage (Equity Multiplier) of TMS Co changed from 1.08 to 1.03, representing a -3.96% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) TMS Co since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s TMS Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — TMS Co

All Key Metrics — TMS Co